Famotidin
When ATH:
A02BA03
Characteristic.
White or pale yellow crystalline powder. It is soluble in acetic acid, poorly - in methanol and water, practically insoluble in ethanol.
Pharmacological action.
Antiulcer.
Application.
Peptic ulcer and duodenal (treatment and prevention of exacerbations), symptomatic ulcers, erosive esophagitis, reflux esophagitis, Zollinger - Ellison, bleeding from the upper gastrointestinal tract (I /), prevention of erosive and ulcerative lesions of the gastrointestinal tract in patients receiving NSAIDs and aspiration of gastric contents during general anesthesia.
Contraindications.
Hypersensitivity, pregnancy, lactation.
Side effects.
Dry mouth, loss of appetite, nausea, vomiting, abdominal discomfort, elevated transaminase levels in the serum, cholestatic jaundice, fatigue, noise in ears, headache, rarely hallucinations, fever, Arrhythmia, myalgia, arthralgia, xerosis, allergic reactions: angioedema, itch, hives, conjunctivitis, bronchospasm; irritation at the injection site.
Cooperation.
At the same time taking famotidine and ketoconazole may decrease the absorption of ketoconazole. In the case of famotidine with antacids the interval between their intake should be at least 1-2 hours.
Overdose.
Symptoms: aggravating side effects.
Treatment: gastric lavage, symptomatic and supportive therapy.
Dosing and Administration.
Inside. When acute gastric ulcer and duodenal ulcer by 40 mg at night or 20 mg 2 times / day (in the morning and in the evening), the duration of the course - 4-8 weeks; to prevent relapse - by 20 mg 1 once daily at night for 6 Months. When reflux esophagitis - 20 mg 1-2 times / day for 6-12 weeks, Zollinger - Ellison - 20-40 mg 4 times / day (if necessary, dose increase).
B / (bolus or infusion). The average dose - 12 mg every 12 no. The syndrome Zollinger - Ellison: the initial dose - 12 mg every 6 no, further adjusting the dose of; for the prevention of aspiration of gastric contents prior to general anesthesia: 20 mg per day of operation or at least 2 hours before its start.
Precautions.
Patients with impaired renal function (Cl creatinine below 30 ml / min) the daily dose is reduced to 20 mg. Children designate drug is not recommended.
In the treatment of gastric ulcer and duodenal ulcer should be excluded in a patient with malignant tumor (study biopsy of ulcer area). To use caution in the human liver.
Cooperation
Active substance | Description of interaction |
Amoksiцillin | FKV. Against the backdrop of accelerating absorption of famotidine. |
Diazepam | FKV. Against the backdrop of slowing famotidine biotransformation. |
Itraconazole | FKV. Against the background of famotidine, alkalizing stomach contents, reduced absorption; when sharing is needed 2 hours (and more) the interval between doses. |
Ketoconazole | FKV. Against the background of famotidine, alkalizing stomach contents, reduced absorption; with a joint appointment needed 2 hours (and more) the interval between doses. |
Magnesium oxide | FKV. Decreases (insignificantly) bioavailability. |
Naproxen | FKV. Against the background of famotidine, alkalizing stomach contents, reduced absorption; concomitant use is not recommended. |
Natriya carbonate | FKV. Decreases (insignificantly) bioavailability. |
Propranolol | FKV. FoNet of famotidine ugnetaetsya biotransformation. |
Sucralfate | FKV. Slows absorption. |
Theophylline | FKV. Against the background of famotidine inhibited biotransformation and increases the concentration in the tissues. |
Fenazon | FKV. FoNet of famotidine ugnetaetsya biotransformation. |
Phenytoin | FKV. FoNet of famotidine ugnetaetsya biotransformation. |